-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
-
Summary
-
Freeline Therapeutics Holdings plc quarterly/annual Research and Development Expense history and growth rate from 2018 to 2022.
- Freeline Therapeutics Holdings plc Research and Development Expense for the quarter ending March 31, 2023 was $10.9M, a 45.4% decline year-over-year.
- Freeline Therapeutics Holdings plc annual Research and Development Expense for 2022 was $66.2M, a 30.6% decline from 2021.
- Freeline Therapeutics Holdings plc annual Research and Development Expense for 2021 was $95.4M, a 25.3% increase from 2020.
- Freeline Therapeutics Holdings plc annual Research and Development Expense for 2020 was $76.1M, a 61.9% increase from 2019.
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Growth (%)